Bullish option flow detected in Apellis Pharmaceuticals with 2,130 calls trading, 1.4x expected, and implied vol increasing over 2 points to 86.51%. Nov-23 50 calls and Nov-23 70 calls are the most active options, with total volume in those strikes near 1,200 contracts. The Put/Call Ratio is 0.12. Earnings are expected on November 1st.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
- Apellis says journal published 24-month result from Phase 3 OAKS, DERBY studies
- The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
- Apellis Pharmaceuticals put volume heavy and directionally bearish
- Apellis to present positive Phase 2 NOBLE results of pegcetacoplan